^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Neuroendocrine Tumor |
| Drug: | Votrient (pazopanib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors
Excerpt:
...Three GEP-NET patients with TP53 mutations demonstrated a durable response to pazopanib, either as PR or achievement of stable disease (Figure 2)…
DOI:
10.18632/oncotarget.6602
